Miruvor
Sign up
The short answer

What studies of Bupropion (Wellbutrin) found

12papers on Bupropion (Wellbutrin)
13people in 4 studies testing Bupropion (Wellbutrin) alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Mixed results

Based on the strongest evidence, studies with no comparison group (very low certainty): 5 findings, all C.

5 outcomes rated · see each below

ME/CFS: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 3 findings, all C.

3 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, studies of Bupropion (Wellbutrin) disagree, so it’s not clear whether it helps. For ME/CFS, Bupropion (Wellbutrin) might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 12 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Bupropion (Wellbutrin) · Long COVID is hereBupropion (Wellbutrin) · ME/CFS is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Cognition (brain fog)2 studies · 3 (few people) people took Bupropion (Wellbutrin) Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance; the studies disagree.

Studies with no comparison group2 studies · 3 people with results (few people)

Studies disagree about cognition (brain fog).

Studies disagree about whether bupropion (Wellbutrin) helps cognition (brain fog). Mixed results · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (3 in all)
  • Not all results were tested against chance
  • The studies disagree
See the 2 studies
  1. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    up to 300 mg/day, at 8 AM
    Outcome
    Effectiveness of LDX 60 mg versus 70 mg
    Effect
    no clear difference
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  2. Can bupropion treat COVID-19-induced brain fog? A case series. (2023)

    People in the study
    2 in the study
    Dose
    —
    Outcome
    brain fog
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 1 (few people) person took Bupropion (Wellbutrin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 18 months · up to 300 mg/day, at 8 AM (few people)

Fatigue improved.

The evidence is very uncertain about the effect of bupropion (Wellbutrin) on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    up to 300 mg/day, at 8 AM
    Outcome
    Fatigue with LDX
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Sleep1 study · 1 (few people) person took Bupropion (Wellbutrin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 18 months · up to 300 mg/day, at 8 AM (few people)

Sleep improved.

The evidence is very uncertain about the effect of bupropion (Wellbutrin) on sleep in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    up to 300 mg/day, at 8 AM
    Outcome
    Insomnia with trazodone
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 1 (few people) person took Bupropion (Wellbutrin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 18 months · up to 300 mg/day, at 8 AM (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of bupropion (Wellbutrin) on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    up to 300 mg/day, at 8 AM
    Outcome
    Medication coverage across all hours
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person took Bupropion (Wellbutrin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 18 months · up to 300 mg/day, at 8 AM (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of bupropion (Wellbutrin) on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. (2023)

    People in the study
    1 in the study
    Dose
    up to 300 mg/day, at 8 AM
    Outcome
    Overall treatment response
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

ME/CFS

Symptoms

Depression2 studies · 10 people took Bupropion (Wellbutrin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (10 in all); not all results were tested against chance.

Studies with no comparison group2 studies · 10 people with results

Depression improved.

The evidence is very uncertain about the effect of bupropion (Wellbutrin) on depression in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (10 in all)
  • Not all results were tested against chance
See the 2 studies
  1. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. (1992)

    People in the study
    9 in the study
    Dose
    300 mg/day
    Outcome
    HDRS Hamilton Depression Rating Scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode. (2006)

    People in the study
    1 in the study
    Dose
    gradually increased to 450 mg/day
    Outcome
    BDI
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms2 studies · 10 people took Bupropion (Wellbutrin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (10 in all); not all results were tested against chance.

Studies with no comparison group2 studies · 10 people with results

Overall symptoms improved.

The evidence is very uncertain about the effect of bupropion (Wellbutrin) on overall symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (10 in all)
  • Not all results were tested against chance
See the 2 studies
  1. Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode. (2006)

    People in the study
    1 in the study
    Dose
    gradually increased to 450 mg/day
    Outcome
    symptoms
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
  2. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. (1992)

    People in the study
    9 in the study
    Dose
    300 mg/day
    Outcome
    responders
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily functioning1 study · 1 (few people) person took Bupropion (Wellbutrin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 6 and 12 months later · gradually increased to 450 mg/day (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of bupropion (Wellbutrin) on daily functioning in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode. (2006)

    People in the study
    1 in the study
    Dose
    gradually increased to 450 mg/day
    Outcome
    part time job
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

Side effects studies reported1 kind
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Trouble sleeping1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    300 mg at the start in most studies

  2. 2Raise

    Raised step by step in 2 of 5 studies

  3. 3Top dose

    Most often 300 mg (3 of 5 studies)

All papers

  1. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome.1992 · no comparison group · 9 in the study
    Summary

    This open study asked whether bupropion would help chronic fatigue syndrome (CFS) patients who had failed a 12-week fluoxetine trial. Nine CFS patients were included; six had not improved on fluoxetine and three were early dropouts with little improvement because they could not tolerate side effects. Patients received bupropion, starting at 200 mg/day and increased to 300 mg/day after 1 week. Clinical assessments were done 4 and 8 weeks after starting treatment, but not all patients completed biological testing (neurochemistry n = 7; immunology n = 6). There was no comparison group. HDRS ratings were 19.7 (SD 7.4) at baseline, essentially unchanged at 4 weeks (18.4, SD 10.9), and 12.5 (SD 10.9) after 8 weeks (t = 4.80, p < 0.01). BDI ratings were 19.8 (SD 15.1) at baseline, minimally changed at 4 weeks (15.7, SD 15.0), and 14.3 (SD 16.0) at the later assessment (t = 2.48, p < 0.05). Six of nine patients were responders, with at least a 40% fall in ratings. Side effects and withdrawals due to harms were not reported. The authors state that the small sample size and open design require replication in a double-blind protocol with larger numbers.

  2. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report.2023 · case report · 1 in the study
    Summary

    A single case study reports a 61-year-old man with Post-COVID-19 Syndrome (PCS) or Long COVID, treated on an outpatient basis and self-referred. He received Immediate-Release Methylphenidate (IR-MPH) started at 5 mg/day and increased to 10 mg TID, then Lisdexamfetamine (LDX) 30 mg upon waking, doubled to 60 mg and soon to 70 mg, with Bupropion XL up to 300 mg/day. The PCS treatment lasted 18 months. ADHD-like symptoms were measured with the Adult ADHD Self-Report Screening Scale (ASRS; total score 0 to 72). Baseline ASRS was 40. IR-MPH initially reduced symptoms to 28 points (30% reduction from baseline); ASRS returned to baseline (40 points) after IR-MPH interruption. Fatigue was fully treated with LDX, but ADHD-like symptoms remained unchanged after some weeks; there was no difference in effectiveness between 60 or 70 mg of LDX. A split LDX plus IR-MPH scheme used for 1 month reduced ASRS to 25 points (37,5% reduction from baseline). After 5 weeks, bupropion add-on reduced ASRS to 17 from the baseline 40 points, a 57,5% reduction and remission of symptoms since the cutoff is 24 points. The final drug combination remained well tolerated. The only adverse effect of the final drug combination was a weight loss of 5 kg that did not disturb the patient; increasing IR-MPH doses was not well tolerated due to insomnia, and the patient did not experience side effects with LDX. Authors state limitations are inherent to a case study and that replication in more patients with PCAS is needed.

  3. Can bupropion treat COVID-19-induced brain fog? A case series.2023 · case report · 2 in the study
    Summary

    This case series describes two people whose brain fog continued after they recovered from acute COVID. Both had memory problems, mental exhaustion and poor attention, with low mood. They were given bupropion extended release, an antidepressant. Doses and the time until symptoms resolved differed between them, but both recovered markedly. The abstract gives no doses, no scores and no information on side effects, and there is no comparison group.

  4. Proceedings #19. Maintenance tDCS: A Case of Full and Durable Recovery from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)2017 · case report · 1 in the study
    Summary

    This conference proceeding reports a case report of one 61-year-old man with treatment-resistant progressive ME/CFS who was referred for neuromodulation. There was no comparison group. He was trained in the office and then self-administered tDCS at home daily, with anode on the left dorsolateral prefrontal cortex, cathode on the right dorsolateral prefrontal cortex, 2 mA/min, 20 minutes, 40 mA total dose, using 1.5” diameter electrode pads. After four weeks, sessions were increased to twice daily (6 AM and 12 Noon). Modafinil 200 mg provided partial relief of fatigue; later the dose was lowered to 100 mg due to insomnia, and modafinil was stopped but resumed at 100 mg daily after he felt less well. The paper reports one year of maintenance tDCS and follow-up neurophysiological studies 14 months after initial presentation. It reports significant benefit early in the day during the first month of daily tDCS, consistent benefit after twice-daily sessions, and full clinical recovery over the next few months, with improved exercise tolerance and a return to physical exercise several times each week. Before treatment, omission errors were 14.29%; after treatment, behavioral measures were within the normal rage and there were no omission errors. The patient reported sustained relief. The authors state that data were not shown for frontocentral infra-slow frequency drift.

  5. Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode.2006 · case report · 1 in the study
    Summary

    This case report described one 39-year-old woman with chronic fatigue syndrome and a coexistent major depression episode, admitted to a psychiatric setting. She was given paroxetine 20 mg/day increased to 40 mg/day, and bupropion was added and gradually increased to 450 mg/day; treatment reached full remission after 6 weeks. There was no comparison group. Symptoms, BDI, MADRS and HAM-D were assessed. After 3 weeks, symptoms improved markedly, reaching full remission after 6 weeks; BDI was 22 at baseline and 5 after 6 weeks, MADRS was 25 and 6, and HAM-D was 22 and 6. On follow-up 6 and 12 months later, symptoms were still absent and she could enter a part time job. After an initial boost of energy, she deteriorated slightly. The authors stated that the report is a case and that controlled studies in larger CFS samples are warranted.

  6. Treatment of chronic fatigue syndrome with venlafaxine.1996 · case report · 2 in the study
  7. Bupropion in chronic fatigue syndrome.1990 · case report · 2 in the study
    Summary

    This letter presents two case reports (no comparison group) of women with chronic fatigue syndrome; the letter does not report where they were treated. Ms. A received bupropion 100 mg b.i.d.; after 1 week she had a complete remission of symptoms, and her Beck Depression Inventory score dropped from 18 to 0. Her respiratory infections, fevers, and fatigue disappeared, and at this low dose there was no return of any symptoms in the following 6 months. Ms. B received bupropion 100 mg t.i.d.; two weeks after starting, her Beck depression score dropped to 7 and her symptoms cleared, with no return of any symptoms in the following 3 months despite major environmental stressors. Harms and withdrawals were not reported. The authors conclude that these two cases of substantial response suggest further clinical research should be directed at bupropion in controlled trials; they do not state a formal limitation.

  8. Overlapping Post-COVID Conditions: A Case of Myalgic Encephalomyelitis and Postural Orthostatic Tachycardia Syndrome Triggered by Sequential Epstein-Barr Virus (EBV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections.2026 · combination: given with other treatments · 1 in the study
    Summary

    This case report describes one 48-year-old woman in Belo Horizonte, Minas Gerais, Brazil, followed at the Carlos Prates Health Center as part of VITA Monitoring. She had ME/CFS diagnosed in early 2023 and POTS diagnosed later that year after SARS-CoV-2 infection in January 2022, with PCC persisting over three years. Her regimen included pyridostigmine bromide 60 mg every 12 hours, duloxetine hydrochloride 60 mg/day (later 30 mg/day), naltrexone 2 mg/day, bupropion 300 mg/day, palmitoylethanolamide 600 mg/day (later 900 mg/day and 1200 mg/day), vitamin C 1 g/day, Omega-3, pacing, hydroxyzine hydrochloride 25 mg/day, methylprednisolone 125 mg/day for three days, and vitamin B12 1 mg/day. Follow-up was baseline (V1) and evaluations after one month (1M), three months (3M), six months (6M), and twelve months (12M). There was no comparison group and no randomisation. The report states partial improvement in fatigue, orthostatic symptoms, and memory, but worsening of hair loss; worsening of symptoms after starting light walks (10 minutes/day); and treatment responses that were partial and fluctuating, with no objective biomarkers available to quantify them. Final assessment in mid-2025 indicated partial, fluctuating symptom response and persistent functional impairment. Harms reported were worsening hair loss and worsening symptoms after starting light walks; withdrawals for harms were not reported. Table 1 presents anthropometric, vital-sign, and handgrip strength measurements descriptively; the authors state changes should not be interpreted as evidence of a treatment effect.

  9. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.2009 · review
    Summary

    This review did not run its own trial; it summarized published data on pharmacological treatment of chronic fatigue syndrome (CFS), identified through a PubMed literature search. The review covers antidepressants and other psychotropic agents in CFS. In included randomized, placebo-controlled trials, moclobemide vs. placebo (47 vs. 43) showed clinically global improvement 51 vs. 33% (OR = 2.16); KPI mean difference between two groups was 0.28 favoring MCB, and Vigor subscale on POMS mean difference was 0.51 favoring MCB. Overall response by subjective global impression was 51% with moclobemide vs. 23% with placebo. At 12 weeks, MIR failed to separate from PBO on FS; at 24 weeks, CBT + MIR showed significantly more reduction in FS scores than PBO + CBT, with an observed difference of 5.5 (95% CI = 15.4 – 22), whereas MIR + CBT failed to separate from PBO + CBT. Fluoxetine failed to separate from PBO on SFS and BDI scores, and failed to demonstrate benefit on listed outcome measures. The review lists harms: TCAs potentially induce sedation and orthostatic hypotension; MAOIs have hypertensive crisis; stimulant medications carry risks of misuse, abuse, withdrawal, and diversion. Authors state research does not support definitive conclusions about antidepressant efficacy in CFS.

  10. The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder.1996 · review
    Summary

    This paper is a review of the literature, not a study of the authors’ own patients; it discusses psychotropic drug treatment of fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder. No setting, enrolment total, comparison group, randomisation or crossover is reported for the review itself. The recorded study within the review is an open study of bupropion in chronic fatigue syndrome: nine patients received 300 mg/day for 8 weeks. Outcomes were the Hamilton Depression Rating Scale and Beck Depression Inventory, and the review states that these nine patients exhibited significant improvement on both after 8 weeks. The review does not report a placebo comparison for this open study, and no harms, withdrawals or side-effect counts are recorded in the provided data. The authors state that the quality of available studies varies widely and that many studies did not systematically evaluate improvement in both physical and psychological symptoms. The summary therefore describes a heterogeneous literature, with only this open bupropion study recorded here.

  11. Chronic Fatigue Syndrome1994 · review
    Summary

    This 1994 review by Bell and Concemi examines psychotropic and immunological treatments for chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME). No single cohort was enrolled; the paper summarizes published treatment trials in patients with CFS, with some related fibromyalgia trials, and settings are not reported. Treatments discussed include tricyclic antidepressants, fluoxetine, sertraline, amfebutamone, cognitive behavioural therapy, immunoglobulin G, mismatched double-stranded RNA, essential fatty acids, transfer factor and other agents. Reported findings are mixed. An open fluoxetine study in 25 patients reported 46% with 'moderate to marked clinical improvement'. A 19-patient intramuscular immunoglobulin G crossover trial reported improvement in 52% versus 32% with placebo; a 37-adult intravenous immunoglobulin G trial found no significant improvements; a 49-patient trial reported 43% versus 12% improvement. In a 92-adult mismatched double-stranded RNA trial, 45 active-drug patients had a median KPS improvement of 8 points while 47 placebo patients showed no improvement. A 70-patient essential fatty acid trial reported 84% versus 22% improvement. In a cognitive therapy report of 50 patients, 22 of 27 were better or much better, 4 unchanged and 1 worse; 5 patients withdrew shortly after starting. Transfer factor was ineffective, aciclovir trials were not successful, and liver extract showed no value over placebo. Some adverse reactions occurred with immunoglobulin G, phlebitis being most common.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime